Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Lixte Biotechnology Holdings ( (LIXT) ) has issued an update.
On July 8, 2025, Lixte Biotechnology Holdings, Inc. announced the closing of a $1.5 million registered direct offering with accredited investors, involving the sale of shares of Common Stock or Pre-Funded Warrants. The proceeds from this offering are intended for general corporate purposes and working capital, potentially impacting the company’s operational capabilities and market positioning in the pharmaceutical industry.
More about Lixte Biotechnology Holdings
Lixte Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on developing and commercializing cancer therapies. The company is pioneering a new field of cancer biology called activation lethality, with its lead compound, LB-100, which is a first-in-class PP2A inhibitor. Lixte’s approach is supported by a comprehensive patent portfolio, and proof-of-concept clinical trials are underway for various cancers.
Average Trading Volume: 1,992,205
Technical Sentiment Signal: Hold
Current Market Cap: $6.01M
See more data about LIXT stock on TipRanks’ Stock Analysis page.